View on GitHub

Pistoia-Alliance-PGO

Pistoia Alliance Pharma General Ontology - One, shared and maintained upper level reference ontology for Pharma.

Class: Biomarker

A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention [https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C16342].

Alternative Descriptions * NCIT | | * PGO | |
Aliases * marker * biological marker
Examples | Value | Description | --- | --- | | Deoxyuridine | https://bioregistry.io/reference/markerdb:/MDB00000007 |
Annotations | property | value | | --- | --- | | definition_source | https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C16342 | | definition_source_attribution | NCI-Thesaurus (NCIT) | | definition_source_licence | [CC-BY-4.0](https://creativecommons.org/licenses/by/4.0/) | | definition_access_date | 2025-05-30 | | expert_approval_date | 2025-06-12 |
Comments * The alignment meeting focused on refining and selecting an ontological definition for the core concept of 'biomarker' within the Pistoia Alliance’s Pharma General Ontology (PGO). Despite the recognized complexity and multidimensionality of the term, only two candidate definitions were formally proposed and evaluated. * Conceptual Context. The term biomarker has been acknowledged in earlier PGO discussions as representing a role, rather than a concrete material entity. This ontological nuance may necessitate additional care in representation, potentially through modeling techniques such as LinkML, to ensure semantic precision and interoperability. * Evaluation of Candidate Definitions. Two primary ontology entries were considered.* NCIT_C16342 (Biomarker, NCI Thesaurus)-- Broadly defined and widely used in clinical and translational research contexts. Received multiple endorsements ([PMQ], [BM], [DH]). Recognized as sufficiently inclusive of the diverse modalities of biomarkers, encompassing molecular, physiological, digital, and behavioral indicators. The definition references core functions such as monitoring normal or pathogenic biological processes, assessing disease risk or prognosis, and predicting or evaluating therapeutic response. While the wording was deemed largely appropriate, some participants suggested that the definition could be further refined to explicitly list specific examples (e.g., 'digital biomarkers', 'imaging biomarkers').* CHEBI_59163 (Biomarker, ChEBI)-- Also proposed by multiple partners, but ultimately considered overly narrow. The definition is constrained by ChEBI’s chemical substance-centric framework, limiting its applicability to non-molecular or non-substance-based biomarkers (e.g., behavioral or digital indicators). * Agreed Text Definition. The following text definition, drawn from NCIT_C16342, was proposed for adoption.'A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.' This definition aligns with established biomedical usage and supports a variety of research and clinical applications. * Recommendations to the PGO Steering Group. 1. Definition Adoption-- Officially adopt NCIT_C16342 as the definition for 'biomarker' within the PGO. 2. Implementation Considerations-- Acknowledge the conceptualization of biomarker as a role, and ensure that implementation models reflect this distinction for ontological consistency and extensibility.
TODOs ## TODOs * Review preferred sources